alexa Synergistic Effect Of Combination 188Re-liposome And Lipotecanin Huh-7 Subcutaneous Xenograft Model
ISSN: 2157-7439

Journal of Nanomedicine & Nanotechnology
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading Please wait..

4th International Conference on Nanotek & Expo
December 01-03, 2014 DoubleTree by Hilton Hotel San Francisco Airport, USA

Po-Yen Liu
Posters: J Nanomed Nanotechnol
DOI: 10.4172/2157-7439.S1.018
The aim of this study was to investigate the therapeutic efficacy of the combination of lipotecan and 188Re-liposome in Huh-7 xenograft tumor model. The Huh-7 subcutaneous transplantation tumor animal model was established to evaluate the antitumor activity of 188Re-liposome combined with lipotecan (188Re-liposome + lipotecan) treatment compared with monotherapy (188Re-liposome or lipotecan). Mice were administered via intravenous injection with 188Re-liposome (8.65 MBq, 2/5 maximum tolerated dose (MTD), lipotecan (48 mg/kg, 2/5MTD) and normal saline as blank control. To evaluate the targeting and localization of 188Re-liposome in Huh-7 tumor-bearing mice, biodistribution was performed. Tumor growth and body weight were measured to evaluate the antitumor effect. After intravenous administration of 188Reliposome, radioactivity in tumors was 2.03?0.46 %ID/g at 24 h, the tumor/muscle ratios is 6.35?0.88 at 24 h. In the study on therapeutic efficacy, the tumor-bearing mice treated with 188Re-liposome + Lipotecan group showed better mean tumor growth inhibition rate (MGI=0.36, n=6) than those treated with radiotherapeutics of 188Re-liposome (MGI=0.681, n=6) and chemotherapeutics of lipotecan (MGI=0.717, n=6). The synergistic tumor regression effect was observed with the combination index (CI) exceeding 1 (CI=1.356) for combination therapy. These results suggest that lipotecan may be usefully integrated into the 188Re-liposome treatment of Huh-7 tumors, with potential benefits resulting from increased tumor cell radiosensitization to preferential targeting of tumor-associated vasculature.
Po-Yen Liu has completed his PhD at the age of 30 years from China Medical University and postdoctoral studies from Institute of Nuclear Energy Research. He has published more than 9 papers in reputed journals.
image PDF   |   image HTML
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version